Global Viral Vector & Plasmid DNA Manufacturing Market Analysis Report 2019-2025 - ResearchAndMarkets.com

The "Viral
Vector & Plasmid DNA Manufacturing Market Analysis Report By
Application, By Disease (Cancer, Genetic), By Workflow (Upstream,
Downstream), By Vector, By End Use, And Segment Forecasts, 2019 - 2025"
report has been added to ResearchAndMarkets.com's
offering.

The global viral vector & plasmid DNA manufacturing market size is
expected to reach USD 882.9 million by 2025, rising at a 16.0% CAGR
during the forecast period.

Rising number of gene therapy-based discovery programs in the pharma
industry is one of the key trends driving the production of gene therapy
vectors. Moreover, a robust pipeline of viral vaccines and gene
therapies has prompted companies to develop novel and effective
technologies for scalable manufacturing of vectors. Current vector
manufacturing process is considered highly regulated, elaborate, and
expensive.

Moreover, at present, there is a shortage of production sites to meet
the demand by the pharmaceutical industry for vector construction
services. These factors have created opportunities for companies to
capitalize on potential avenues in the market through developing novel
solutions.

Key growth strategies adopted by companies to sustain their market
presence include continuous expansion of manufacturing sites in
high-demand markets such as the U.S. and U.K. Moreover, companies are
engaged in strategic mergers & facility acquisitions to meet growing
requirements of viral vectors within the pharmaceutical and biotech
industries and to broaden their service portfolios.

Further Key Findings From the Report Suggest:

• Adenovirus and retrovirus were prominent vector type segments in the
  market in 2017. These can be produced at high titers and induce a
  strong humoral and, especially, a strong T cell response, as a result
  of which these vector type is extensively employed in vaccines
• Lentiviral production costs nearly up to 40.0% of the total cost of
  goods, thus inducing revenue growth in this vector type
• Downstream processing accounted for the largest share in 2017, owing
  to requirement of expensive equipment and skilled personnel for
  product recovery
• In terms of application, vector manufacturing for antisense, RNAi, &
  molecular therapy production represented the leading revenue share in
  2017. This is due to high adoption rate of viruses for oligonucleotide
  and aptamers development in comparison to other applications
• The number of biotech companies that are engaged in employing vector
  for therapeutic production continue to increase over the period
• Recent approval of cancer gene therapy products encourages further
  efforts in this arena, thus resulting in the cancer segment holding
  the dominant revenue share
• North America led the global market owing to presence of several
  universities and research institutes that are engaged in genomic
  research programs
• Cobra Biologics, Merck, uniQure N.V., and Novasep are some key
  participants that are focusing towards capitalizing of untapped
  avenues in the market.

Key Topics Covered:

Chapter 1 Executive Summary

1.1 Market Snapshot

Chapter 2 Research Methodology

2.1 Information Procurement
2.2 Data Analysis
2.3 Market
Formulation & Validation
2.4 Approaches for Market Estimation

Chapter 3 Viral Vector & Plasmid DNA Manufacturing Market
Variables, Trends & Scope

3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1
Robust pipeline for gene therapies and viral vector vaccines
3.1.1.2
Technological advancements for vector production
3.1.1.3 Highly
competitive market and various marketing strategies undertaken by the
operating entities
3.1.2 Market restraint analysis
3.1.2.1
Regulatory, scientific, and ethical challenges associated with gene
therapy
3.1.3 Challenge analysis
3.1.3.1 Production capacity
challenges
3.1.3.2 Manufacturing challenges pertaining to the
production of vector at large scale
3.1.4 Opportunity analysis
3.1.4.1
Facility expansion for cell and gene therapies
3.1.4.2 Investments,
collaboration & partnerships in cell and gene therapies space
3.2
Penetration & Growth Prospect Mapping For Vector Type, 2017
3.3
Viral Vector & Plasmid DNA Manufacturing Market-Swot Analysis, By Factor
(Political & Legal, Economic And Technological)
3.4 Industry
Analysis - Porter's

Chapter 4 Viral Vector & Plasmid DNA Manufacturing Market
Categorization: Vector Type Estimates & Trend Analysis

4.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type
Movement Analysis
4.2 Adenovirus
4.3 Retrovirus
4.4
Plasmid DNA
4.5 AAV
4.6 Lentivirus
4.7 Other Vectors

Chapter 5 Viral Vector & Plasmid DNA Manufacturing Market
Categorization: Workflow Estimates & Trend Analysis

5.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement
Analysis
5.2 Upstream Manufacturing
5.2.2 Vector amplification
& expansion
5.2.3 Vector recovery/harvesting
5.3
Downstream Manufacturing
5.3.2 Purification
5.3.3 Fill-finish

Chapter 6 Viral Vector & Plasmid DNA Manufacturing Market
Categorization: Application Estimates & Trend Analysis

6.1 Viral Vector & Plasmid DNA Manufacturing Market: Application
Movement Analysis
6.2 Antisense, RNAi, & Molecular Therapy
6.3
Vaccinology

Chapter 7 Viral Vector & Plasmid DNA Manufacturing Market
Categorization: End-use Estimates & Trend Analysis

7.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement
Analysis
7.2 Pharmaceutical and Biopharmaceutical Companies|
7.3
Research Institutes

Chapter 8 Viral Vector & Plasmid DNA Manufacturing Market
Categorization: Disease Estimates & Trend Analysis

8.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement
Analysis
8.2 Cancer
8.3 Genetic disorders
8.4 Infectious
diseases
8.5 Others

Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market
Categorization: Regional Estimates & Trend Analysis

9.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional,
2017 & 2025
9.2 North America
9.3 Europe
9.4 Asia
Pacific
9.5 Latin America
9.6 MEA

Chapter 10 Competitive Landscape

10.1 List of Companies With Portfolio for Vector-based Therapeutic
Candidate
10.2 List of Vector Manufacturers
10.3 Strategy
Framework
10.4 Market Participation Categorization
10.5
Company Profiles

• Merck KGaA
• Lonza
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Cobra Biologics Ltd.
• Brammer Bio
• Waisman Biomanufacturing
• Genezen
• Yposkesi
• Regenxbio, Inc.
• Cell and Gene Therapy Catapult

For more information about this report visit https://www.researchandmarkets.com/research/dxb9s4/global_viral?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005404/en/